Rocket Pharmaceuticals (RCKT) Competitors

$3.54 -0.07 (-1.94%)

Closing price 04:00 PM Eastern

Extended Trading

$3.52 -0.02 (-0.71%)

As of 04:54 PM Eastern

RCKT vs. OCS, IMTX, MBX, DMRA, and BHVN

Should you be buying Rocket Pharmaceuticals stock or one of its competitors? The main competitors of Rocket Pharmaceuticals include Oculis (OCS), Immatics (IMTX), MBX Biosciences (MBX), Damora Therapeutics, Inc. Common Stock (DMRA), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry.

How does Rocket Pharmaceuticals compare to Oculis?

Oculis (NASDAQ:OCS) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

: Oculis has higher revenue and earnings than Rocket Pharmaceuticals. Oculis is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Oculis $1.45M 1,109.62 -$119.44M -$2.27 N/A
Rocket Pharmaceuticals N/A N/A -$223.12M -$2.01 N/A
: 22.3% of Oculis shares are owned by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 21.3% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
: In the previous week, Oculis had 7 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 8 mentions for Oculis and 1 mentions for Rocket Pharmaceuticals. Oculis' average media sentiment score of 0.97 beat Rocket Pharmaceuticals' score of 0.00 indicating that Oculis is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oculis
4 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Rocket Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Rocket Pharmaceuticals has a net margin of 0.00% compared to Oculis' net margin of -8,173.41%. Oculis' return on equity of -62.12% beat Rocket Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Oculis -8,173.41% -62.12% -49.74%
Rocket Pharmaceuticals N/A -64.74% -55.24%
: Oculis currently has a consensus target price of $43.86, indicating a potential upside of 58.04%. Rocket Pharmaceuticals has a consensus target price of $13.86, indicating a potential upside of 291.44%. Given Rocket Pharmaceuticals' higher probable upside, analysts plainly believe Rocket Pharmaceuticals is more favorable than Oculis.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oculis
1 Sell rating(s)
0 Hold rating(s)

7 Buy rating(s)

0 Strong Buy rating(s)
2.75
Rocket Pharmaceuticals
3 Sell rating(s)

6 Hold rating(s)

8 Buy rating(s)

1 Strong Buy rating(s)
2.39
: Oculis has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	1,109.62	-$119.44M	-$2.27	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$2.01	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rocket Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,173.41%	-62.12%	-49.74%
Rocket Pharmaceuticals	N/A	-64.74%	-55.24%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75
Rocket Pharmaceuticals	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39

Summary

Rocket Pharmaceuticals beats Oculis on 9 of the 16 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Immatics?

Immatics (NASDAQ:IMTX) and Rocket Pharmaceuticals (NASDAQ:RCKT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

: Immatics has higher revenue and earnings than Rocket Pharmaceuticals. Immatics is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Immatics $48.27M 30.42 -$222.26M -$1.84 N/A
Rocket Pharmaceuticals N/A N/A -$223.12M -$2.01 N/A
: 64.4% of Immatics shares are owned by institutional investors. Comparatively, 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 21.3% of Rocket Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: In the previous week, Immatics had 2 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 3 mentions for Immatics and 1 mentions for Rocket Pharmaceuticals. Rocket Pharmaceuticals' average media sentiment score of 0.00 beat Immatics' score of -0.25 indicating that Rocket Pharmaceuticals is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immatics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Rocket Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Rocket Pharmaceuticals has a net margin of 0.00% compared to Immatics' net margin of -411.90%. Immatics' return on equity of -41.81% beat Rocket Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Immatics -411.90% -41.81% -34.72%
Rocket Pharmaceuticals N/A -64.74% -55.24%
: Immatics currently has a consensus target price of $19.00, indicating a potential upside of 73.52%. Rocket Pharmaceuticals has a consensus target price of $13.86, indicating a potential upside of 291.44%. Given Rocket Pharmaceuticals' higher probable upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than Immatics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immatics
1 Sell rating(s)
1 Hold rating(s)

7 Buy rating(s)

0 Strong Buy rating(s)
2.67
Rocket Pharmaceuticals
3 Sell rating(s)

6 Hold rating(s)

8 Buy rating(s)

1 Strong Buy rating(s)
2.39
: Immatics has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$48.27M	30.42	-$222.26M	-$1.84	N/A
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$2.01	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rocket Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-411.90%	-41.81%	-34.72%
Rocket Pharmaceuticals	N/A	-64.74%	-55.24%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Rocket Pharmaceuticals	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39

Summary

Immatics and Rocket Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to MBX Biosciences?

Rocket Pharmaceuticals (NASDAQ:RCKT) and MBX Biosciences (NASDAQ:MBX) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

: Rocket Pharmaceuticals currently has a consensus target price of $13.86, suggesting a potential upside of 291.44%. MBX Biosciences has a consensus target price of $53.25, suggesting a potential upside of 79.90%. Given Rocket Pharmaceuticals' higher possible upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than MBX Biosciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rocket Pharmaceuticals
3 Sell rating(s)
6 Hold rating(s)

8 Buy rating(s)

1 Strong Buy rating(s)
2.39
MBX Biosciences
2 Sell rating(s)

0 Hold rating(s)

9 Buy rating(s)

1 Strong Buy rating(s)
2.75
: MBX Biosciences is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Rocket Pharmaceuticals N/A N/A -$223.12M -$2.01 N/A
MBX Biosciences N/A N/A -$86.97M -$2.41 N/A
: In the previous week, Rocket Pharmaceuticals had 1 more articles in the media than MBX Biosciences. MarketBeat recorded 1 mentions for Rocket Pharmaceuticals and 0 mentions for MBX Biosciences. Rocket Pharmaceuticals' average media sentiment score of 0.00 equaled MBX Biosciences'average media sentiment score.
Company Overall Sentiment
Rocket Pharmaceuticals Neutral
MBX Biosciences Neutral
: 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. 21.3% of Rocket Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: Rocket Pharmaceuticals has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, MBX Biosciences has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500.
: MBX Biosciences' return on equity of -28.72% beat Rocket Pharmaceuticals' return on equity.
Company Net Margins Return on Equity Return on Assets
Rocket Pharmaceuticals N/A -64.74% -55.24%
MBX Biosciences N/A -28.72% -27.55%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$2.01	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A

Company	Overall Sentiment
Rocket Pharmaceuticals	Neutral
MBX Biosciences	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-64.74%	-55.24%
MBX Biosciences	N/A	-28.72%	-27.55%

Summary

Rocket Pharmaceuticals and MBX Biosciences tied by winning 6 of the 12 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Damora Therapeutics, Inc. Common Stock?

Rocket Pharmaceuticals (NASDAQ:RCKT) and Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

: Rocket Pharmaceuticals currently has a consensus target price of $13.86, suggesting a potential upside of 291.44%. Damora Therapeutics, Inc. Common Stock has a consensus target price of $43.40, suggesting a potential upside of 74.51%. Given Rocket Pharmaceuticals' higher possible upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than Damora Therapeutics, Inc. Common Stock.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rocket Pharmaceuticals
3 Sell rating(s)
6 Hold rating(s)

8 Buy rating(s)

1 Strong Buy rating(s)
2.39
Damora Therapeutics, Inc. Common Stock
1 Sell rating(s)

1 Hold rating(s)

4 Buy rating(s)

2 Strong Buy rating(s)
2.88
: Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Rocket Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Rocket Pharmaceuticals N/A N/A -$223.12M -$2.01 N/A
Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$12.10 N/A
: In the previous week, Damora Therapeutics, Inc. Common Stock had 2 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 3 mentions for Damora Therapeutics, Inc. Common Stock and 1 mentions for Rocket Pharmaceuticals. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 1.02 beat Rocket Pharmaceuticals' score of 0.00 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rocket Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Damora Therapeutics, Inc. Common Stock
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. 21.3% of Rocket Pharmaceuticals shares are owned by insiders. Comparatively, 10.5% of Damora Therapeutics, Inc. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: Rocket Pharmaceuticals has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Damora Therapeutics, Inc. Common Stock has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500.
: Rocket Pharmaceuticals' return on equity of -64.74% beat Damora Therapeutics, Inc. Common Stock's return on equity.
Company Net Margins Return on Equity Return on Assets
Rocket Pharmaceuticals N/A -64.74% -55.24%
Damora Therapeutics, Inc. Common Stock N/A -147.05% -279.49%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$2.01	N/A
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$12.10	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Damora Therapeutics, Inc. Common Stock	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-64.74%	-55.24%
Damora Therapeutics, Inc. Common Stock	N/A	-147.05%	-279.49%

Summary

Rocket Pharmaceuticals beats Damora Therapeutics, Inc. Common Stock on 8 of the 14 factors compared between the two stocks.

How does Rocket Pharmaceuticals compare to Biohaven?

Rocket Pharmaceuticals (NASDAQ:RCKT) and Biohaven (NYSE:BHVN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

: In the previous week, Biohaven had 8 more articles in the media than Rocket Pharmaceuticals. MarketBeat recorded 9 mentions for Biohaven and 1 mentions for Rocket Pharmaceuticals. Biohaven's average media sentiment score of 0.82 beat Rocket Pharmaceuticals' score of 0.00 indicating that Biohaven is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rocket Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Biohaven
1 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
: Rocket Pharmaceuticals' return on equity of -64.74% beat Biohaven's return on equity.
Company Net Margins Return on Equity Return on Assets
Rocket Pharmaceuticals N/A -64.74% -55.24%
Biohaven N/A -688.89% -158.04%
: Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Rocket Pharmaceuticals N/A N/A -$223.12M -$2.01 N/A
Biohaven N/A N/A -$738.82M -$6.96 N/A
: 98.4% of Rocket Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.8% of Biohaven shares are owned by institutional investors. 21.3% of Rocket Pharmaceuticals shares are owned by insiders. Comparatively, 13.8% of Biohaven shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: Rocket Pharmaceuticals currently has a consensus target price of $13.86, suggesting a potential upside of 291.44%. Biohaven has a consensus target price of $22.47, suggesting a potential upside of 131.45%. Given Rocket Pharmaceuticals' higher possible upside, analysts clearly believe Rocket Pharmaceuticals is more favorable than Biohaven.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rocket Pharmaceuticals
3 Sell rating(s)
6 Hold rating(s)

8 Buy rating(s)

1 Strong Buy rating(s)
2.39
Biohaven
1 Sell rating(s)

5 Hold rating(s)

9 Buy rating(s)

3 Strong Buy rating(s)
2.78
: Rocket Pharmaceuticals has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Biohaven has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biohaven	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Rocket Pharmaceuticals	N/A	-64.74%	-55.24%
Biohaven	N/A	-688.89%	-158.04%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket Pharmaceuticals	N/A	N/A	-$223.12M	-$2.01	N/A
Biohaven	N/A	N/A	-$738.82M	-$6.96	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket Pharmaceuticals	3 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.39
Biohaven	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.78

Summary

Rocket Pharmaceuticals and Biohaven tied by winning 7 of the 14 factors compared between the two stocks.

Get Rocket Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RCKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RCKT vs. The Competition

Export

Metric	Rocket Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$386.30M	$3.39B	$6.25B	$11.87B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	-1.76	38.85	29.04	28.47
Price / Sales	N/A	155.51	476.61	60.92
Price / Cash	N/A	57.88	27.62	36.52
Price / Book	1.38	7.03	9.67	6.67
Net Income	-$223.12M	$23.62M	$3.55B	$332.53M
7 Day Performance	3.21%	3.68%	1.70%	2.01%
1 Month Performance	-0.28%	7.16%	5.62%	9.19%
1 Year Performance	-54.90%	67.05%	34.41%	39.59%

Rocket Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RCKT Rocket Pharmaceuticals	2.1842 of 5 stars	$3.54 -1.9%	$13.86 +291.4%	N/A	$386.30M	N/A	N/A	240
OCS Oculis	3.7103 of 5 stars	$27.12 +2.6%	$43.86 +61.7%	N/A	$1.53B	$1.45M	N/A	2	Upcoming Earnings High Trading Volume
IMTX Immatics	2.149 of 5 stars	$11.35 flat	$19.00 +67.4%	N/A	$1.52B	$54.60M	N/A	260	Upcoming Earnings Analyst Downgrade
MBX MBX Biosciences	2.3707 of 5 stars	$31.97 +0.0%	$53.25 +66.6%	N/A	$1.52B	N/A	N/A	N/A
DMRA Damora Therapeutics, Inc. Common Stock	2.8181 of 5 stars	$25.50 +3.0%	$43.40 +70.2%	N/A	$1.49B	N/A	N/A	40	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RCKT) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rocket Pharmaceuticals (RCKT) Competitors

RCKT vs. OCS, IMTX, MBX, DMRA, and BHVN

How does Rocket Pharmaceuticals compare to Oculis?

Summary

How does Rocket Pharmaceuticals compare to Immatics?

Summary

How does Rocket Pharmaceuticals compare to MBX Biosciences?

Summary

How does Rocket Pharmaceuticals compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Rocket Pharmaceuticals compare to Biohaven?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT vs. The Competition

Rocket Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rocket Pharmaceuticals (RCKT) Competitors

RCKT vs. OCS, IMTX, MBX, DMRA, and BHVN

How does Rocket Pharmaceuticals compare to Oculis?

Summary

How does Rocket Pharmaceuticals compare to Immatics?

Summary

How does Rocket Pharmaceuticals compare to MBX Biosciences?

Summary

How does Rocket Pharmaceuticals compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Rocket Pharmaceuticals compare to Biohaven?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCKT vs. The Competition

Rocket Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools